Mark M. Yarchoan

机构：Bloomberg (United States), Johns Hopkins University, Johns Hopkins Medicine, Sidney Kimmel Cancer Center, Convergence, Sidney Kimmel Comprehensive Cancer Center, University of Baltimore · ORCID：0000-0003-4401-0748

发表论文 528 篇 · 总被引 19014 次 · h-index 53

代表论文

Supplementary Data1 from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Data from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Supplementary Data2 from A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer (2026)
Dynamic Spatial Tumor–Immune Remodeling Drives Response and Resistance to ICI plus Chemotherapy in Metastatic Gastric Cancer (2026 · Zenodo (CERN European Organization for Nuclear Research))
Dynamic Spatial Tumor–Immune Remodeling Drives Response and Resistance to ICI plus Chemotherapy in Metastatic Gastric Cancer (2026 · Zenodo (CERN European Organization for Nuclear Research))
Supplemental Figure 9 from Peripheral Th17 Immune Signature Associates with Excellent Response to Anti–PD-1/Anti–PD-L1 Therapy across Solid Tumors (2026)